Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
ANI Pharmaceuticals Inc (ANIP)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/25/2025: ANIP (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Analysis of Past Performance
Type Stock | Historic Profit 27.85% | Avg. Invested days 54 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 03/25/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.48B USD | Price to earnings Ratio - | 1Y Target Price 81.5 |
Price to earnings Ratio - | 1Y Target Price 81.5 | ||
Volume (30-day avg) 320238 | Beta 0.63 | 52 Weeks Range 52.50 - 70.00 | Updated Date 04/1/2025 |
52 Weeks Range 52.50 - 70.00 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.04 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -3.02% | Operating Margin (TTM) 0.8% |
Management Effectiveness
Return on Assets (TTM) 0.84% | Return on Equity (TTM) -4.18% |
Valuation
Trailing PE - | Forward PE 10.88 | Enterprise Value 1885688064 | Price to Sales(TTM) 2.37 |
Enterprise Value 1885688064 | Price to Sales(TTM) 2.37 | ||
Enterprise Value to Revenue 3.21 | Enterprise Value to EBITDA 31.2 | Shares Outstanding 21762600 | Shares Floating 15627749 |
Shares Outstanding 21762600 | Shares Floating 15627749 | ||
Percent Insiders 11.22 | Percent Institutions 97.39 |
Analyst Ratings
Rating 4.17 | Target Price 78.67 | Buy 3 | Strong Buy 2 |
Buy 3 | Strong Buy 2 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
ANI Pharmaceuticals Inc
Company Overview
History and Background
ANI Pharmaceuticals, Inc. was founded in 2003. Initially focused on contract manufacturing, it transitioned to developing and marketing its own branded and generic pharmaceutical products through strategic acquisitions and internal development. A key milestone was the acquisition of certain generic drug product lines from Teva in 2016.
Core Business Areas
- Generics: Development, manufacturing, and marketing of generic pharmaceutical products across various therapeutic areas.
- Branded Pharmaceuticals: Development and commercialization of branded pharmaceutical products, including Cortenema and Lithobid.
- Contract Manufacturing: Manufacturing services for third-party pharmaceutical companies.
Leadership and Structure
Nikhil Lalwani serves as the President and CEO. The organizational structure is typical of a pharmaceutical company, with departments focusing on R&D, manufacturing, sales, marketing, finance, and regulatory affairs.
Top Products and Market Share
Key Offerings
- Cortenema: A branded rectal corticosteroid used to treat ulcerative colitis. Market share data is not readily available. Competitors include other corticosteroid formulations and biologics.
- Market Share (%): Market share unavailable
- Lithobid: A branded sustained-release lithium carbonate product used to treat bipolar disorder. Market share data is not readily available. Competitors include other lithium formulations and mood stabilizers.
- Market Share (%): Market share unavailable
- Generic Drugs: A portfolio of generic pharmaceutical products across various therapeutic areas including anti-inflammatory, pain management, and anti-infectives. Market share varies by product. Competitors include Teva, Mylan (Viatris), and Sun Pharma.
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by high R&D costs, stringent regulatory requirements, and intense competition. The generic drug market is driven by patent expirations and cost-containment pressures, while the branded drug market focuses on innovation and marketing.
Positioning
ANI Pharmaceuticals positions itself as a specialty pharmaceutical company focused on developing and marketing both branded and generic products. Its competitive advantages include its diversified product portfolio and manufacturing capabilities.
Total Addressable Market (TAM)
The global pharmaceutical market is estimated to be over $1 trillion. ANI's TAM focuses on specific segments within the generic and branded drug markets. Actual TAM is dependent on portfolio of marketed drugs.
Upturn SWOT Analysis
Strengths
- Diversified product portfolio
- Manufacturing capabilities
- Experienced management team
- Established distribution network
- Focus on niche markets
Weaknesses
- Dependence on key products
- Exposure to generic competition
- Limited R&D resources compared to larger players
- Smaller market capitalization than peers
Opportunities
- Acquisitions of complementary products or companies
- Expansion into new therapeutic areas
- Strategic partnerships with larger pharmaceutical companies
- Development of biosimilars
Threats
- Increased generic competition
- Pricing pressures from payers
- Regulatory changes
- Product liability lawsuits
- Economic downturns
Competitors and Market Share
Key Competitors
- TEVA
- VTRS
- RDY
Competitive Landscape
ANI Pharmaceuticals faces intense competition from larger generic and branded pharmaceutical companies. Its advantages include its diversified product portfolio and manufacturing capabilities. Disadvantages include its smaller size and limited R&D resources.
Major Acquisitions
Alimera Sciences, Inc
- Year: 2024
- Acquisition Price (USD millions): 82.5
- Strategic Rationale: Acquisition to expand ophthalmology offering with ILUVIENu00ae for diabetic macular edema (DME).
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by acquisitions, new product launches, and increasing sales of existing products.
Future Projections: Future growth projections vary depending on analyst estimates and management guidance. Key factors influencing growth include new product development, acquisitions, and market conditions.
Recent Initiatives: Recent strategic initiatives have included acquisitions of new products, cost reduction programs, and investments in R&D.
Summary
ANI Pharmaceuticals is a specialty pharmaceutical company operating in a competitive landscape. Its diversified portfolio and manufacturing capabilities are key strengths. The company needs to manage generic competition and pricing pressures, while leveraging acquisition opportunities and strategic partnerships. Overall, ANI is in fair position and should remain watchful to the risks that it faces.
Similar Companies
PRGO
Perrigo Company PLC
PRGO
Perrigo Company PLC
RDY
Dr. Reddy’s Laboratories Ltd ADR
RDY
Dr. Reddy’s Laboratories Ltd ADR
TEVA
Teva Pharma Industries Ltd ADR
TEVA
Teva Pharma Industries Ltd ADR
VTRS
Viatris Inc
VTRS
Viatris Inc
Sources and Disclaimers
Data Sources:
- ANI Pharmaceuticals Investor Relations
- SEC Filings (10-K, 10-Q)
- Third-party financial data providers
- Industry reports
Disclaimers:
The data provided is for informational purposes only and should not be considered investment advice. Market share data is estimated and may not be precise. Financial data is not real-time and should be verified with official sources. AI rating is generated with available information.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About ANI Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Baudette, MN, United States | ||
IPO Launch date 2000-05-05 | President, CEO & Director Mr. Nikhil Lalwani | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 897 | |
Full time employees 897 | |||
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. It markets, sells, and distributes its products through wholesalers, retail market chains, distributors and specialty pharmacies, group purchasing organizations, specialty pharmacies, hospitals, clinics, and physicians. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.